indoles and allyl acetates/alcohols. The reaction tolerates many functional groups and selectively affords the branched C3-allylated products from both α- and γ-substituted allyl substrates. It takes the advantage of the hemilabile character of the P∧N ligand. The C(sp2)–C(sp3) coupling operates via a Au(I)/Au(III) redox cycle and involves a dicationic π-allyl Au(III) complex as a key intermediate. In this
Isocyanide-Induced Activation of Copper Sulfate: Direct Access to Functionalized Heteroarene Sulfonic Esters
作者:Xiaohu Hong、Qitao Tan、Bingxin Liu、Bin Xu
DOI:10.1002/anie.201612565
日期:2017.3.27
direct approach to alkyl/aryl heteroarene sulfonic esters using copper sulfate as the environmentally benign inorganic sulfonation reagent was first realized with the aid of isocyanide. A variety of heterocycles reacted to afford the corresponding sulfonic esters through C−H functionalization. In this transformation, the otherwise inert copper sulfate was unusually activated by an isocyanide and employed
Palladium-Catalyzed Three-Component Regioselective Dehydrogenative Coupling of Indoles, 2-Methylbut-2-ene, and Carboxylic Acids
作者:Xing-Long Zhang、Rui-Li Guo、Meng-Yue Wang、Bao-Yin Zhao、Qiong Jia、Jin-Hui Yang、Yong-Qiang Wang
DOI:10.1021/acs.orglett.1c03776
日期:2021.12.17
Five-carbon (C5) structural units are the fundamental building blocks of many natural products. An unprecedented palladium-catalyzed three-component dehydrogenative cascade coupling of indoles, 2-methylbut-2-ene, and carboxylicacids has been developed. The approach enables the straightforward introduction of a C3′-bonded five-carbon structural unit with a tertiary alcohol quaternary carbon center
The present invention is concerned with aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives of formula I
wherein
R
1
, R
2
, R
3
, R
4
, and R
5
are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. The invention also relates to methods for preparing such compounds. This class of compounds has a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. Thus, the invention also is concerned with pharmaceutical compositions containing compounds of formula I or their pharmaceutically acceptable acid addition salts and methods for the treatment of GABA A α5 mediated diseases, including Alzheimer's disease.
本发明涉及式I的芳基异噁唑-4-羰基吲哚羧酸酰胺衍生物,其中R1、R2、R3、R4和R5如规范和权利要求中所定义,并且其药学上可接受的酸加成盐。本发明还涉及制备这种化合物的方法。这类化合物对GABA A α5受体结合位点具有高亲和力和选择性,可能有助于认知增强或治疗像阿尔茨海默病这样的认知障碍。因此,本发明还涉及含有式I化合物或其药学上可接受的酸加成盐的制药组合物以及治疗GABA A α5介导疾病,包括阿尔茨海默病的方法。
Substituted anilinic piperidines as MCH selective antagonists
申请人:Marzabadi R. Mohammad
公开号:US20070043080A1
公开(公告)日:2007-02-22
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.